Evaluation of Marine Diindolinonepyrane in Vitro and in Vivo: Permeability Characterization in Caco-2 Cells Monolayer and Pharmacokinetic Properties in Beagle Dogs

oleh: Zibin Ma, Ruihua Guo, Jeevithan Elango, Bin Bao, Wenhui Wu

Format: Article
Diterbitkan: MDPI AG 2019-11-01

Deskripsi

A marine fibrinolytic compound was studied for use in thrombolytic therapy. Firstly, the absorption and transportation characteristics of 2,5-B<i>H</i>PA (2,5-B<i>H</i>PA:2,5-Bis-[8-(4,8-dimethyl-nona-3,7-dienyl)-5,7-dihydroxy-8-methyl-3-keto-1,2,7,8-tertahydro-6<i>H</i>-pyran[a]isoindol-2-yl]-pentanoic acid, a novel pyran-isoindolone derivative with bioactivity isolated from a rare marine microorganism in our laboratory) in the human Caco-2 cells monolayer model were investigated. We collected 2,5-B<i>H</i>PA in the cells to calculate the total recovery, and its concentration was analyzed by LC/MS/MS (Liquid Chromatography/ Mass Spectrum/ Mass Spectrum). The results showed that 2,5-B<i>H</i>PA has low permeability and low total recoveries in the Caco-2 cells membrane. Pharmacokinetics and tissue distribution of 2,5-B<i>H</i>PA were investigated in beagle dogs using HPLC (High Performance Liquid Chromatography) after intravenous administration of three different doses (7.5, 5.0, 2.5 mg&#183;kg<sup>&#8722;1</sup>). Pharmacokinetic data indicated that 2,5-B<i>H</i>PA fitted well to a two-compartment model. Elimination half-lives (T<sub>1/2</sub>) were 49 &#177; 2, 48 &#177; 2, and 49 &#177; 2 min, respectively; the peak concentrations (C<sub>max</sub>) were 56.48 &#177; 6.23, 48.63 &#177; 5.53, and 13.64 &#177; 2.76 &#956;g&#183;mL<sup>&#8722;1</sup>, respectively; clearance rates (CL) were 0.0062 &#177; 0.0004, 0.0071 &#177; 0.0008, and 0.0092 &#177;0.0006 L&#183;min<sup>&#8722;1</sup>&#183;kg<sup>&#8722;1</sup>, respectively; mean retention times (MRT) were 28.17 &#177; 1.16, 26.23 &#177; 0.35, and 28.66 &#177; 0.84 min, respectively. The low penetrability of 2,5-B<i>H</i>PA indicated that the intravenous route of administration is more appropriate than the oral route. Meanwhile, 2,5-B<i>H</i>PA showed a good pharmacokinetic profile in beagle dogs. The tissue distribution showed that 2,5-B<i>H</i>PA could quickly distribute into the heart, intestines, liver, stomach, spleen, lungs, testicles, urine, intestine, kidneys, brain, and feces. The concentration of 2,5-B<i>H</i>PA was higher in the liver and bile. Interestingly, 2,5-B<i>H</i>PA was detected in the brain. Taken together, the above results suggested that our work might be beneficial in the development of agents for thrombolytic treatment.